Esperion Therapeutics, Inc. ESPR

Latest FY: 2025 Healthcare Drug Manufacturers - Specialty & Generic
Market Price $3.19
Market Cap $821.21M
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑21.3% YoY
$403.13M
3-Yr CAGR: 74.8%
Net Income ↑56.2% YoY
-$22.68M
Net Margin: -5.6%
Free Cash Flow ↑45.4% YoY
-$13.09M
FCF Yield: -1.59%
EPS (Diluted) ↑60.7% YoY
$-0.11
Basic: $-0.11
Return on Equity Efficiency
N/A
ROA: -4.9%
⚡ N/A due to negative equity (share buybacks or other)

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (ESPR)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $-57.9M $-75.0M $-3.33 $-47.7M $-47.8M
FY 2017 $-147.6M $-167.0M -122.7% $-6.98 -109.6% $-131.3M $-131.3M -174.6%
FY 2018 $-201.8M -20.9% $-7.54 -8.0% $-148.6M $-148.8M -13.3%
FY 2019 $148.4M $140.2M $-97.2M +51.9% $-3.59 +52.4% $-70.3M $-71.3M +52.1%
FY 2020 $227.5M +53.4% $204.9M $-143.6M -47.7% $-5.23 -45.7% $-85.2M $-86.0M -20.7%
FY 2021 $78.4M -65.5% $32.1M $-269.1M -87.5% $-9.31 -78.0% $-263.8M $-263.8M -206.6%
FY 2022 $75.5M -3.8% $48.5M $-233.7M +13.2% $-3.52 +62.2% $-174.8M $-174.8M +33.7%
FY 2023 $116.3M +54.1% $73.1M $-209.2M +10.4% $-2.03 +42.3% $-135.5M $-135.5M +22.5%
FY 2024 $332.3M +185.7% $263.7M $-51.7M +75.3% $-0.28 +86.2% $-23.7M $-24.0M +82.3%
FY 2025 $403.1M +21.3% $273.9M $-22.7M +56.2% $-0.11 +60.7% $-13.1M $-13.1M +45.4%
$

Valuation

Market Price $3.19
Market Cap $821.21M
Enterprise Value $805.57M
P/E Ratio N/A
P/B Ratio N/A
FCF Yield -1.59%
Dividend Yield N/A
Shares Outstanding 257,431,899
%

Profitability & Margins

Gross Margin 67.95%
Operating Margin 14.95%
Net Margin -5.63%
Return on Equity (ROE) N/A (Negative Equity)
Return on Assets (ROA) -4.87%
Asset Turnover 0.87x
Revenue 3-Yr CAGR 74.80%
🛡️

Financial Health & Liquidity

Current Ratio 1.54
Cash Ratio 0.56
Debt / Equity -0.504
Debt / Assets 0.327
Cash & Equivalents $167.85M
Total Debt $152.22M
Book Value / Share $-1.17
💧

Cash Flow Efficiency

Operating Cash Flow -$13.09M
Capital Expenditures (CapEx) N/A
Free Cash Flow -$13.09M
OCF / Revenue -3.25%
FCF / Revenue -3.25%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-0.11
EPS (Basic) $-0.11
Dividends / Share N/A
Book Value / Share $-1.17
EPS YoY Growth 60.71%
🏛️

Balance Sheet (FY 2025)

Total Assets $465.89M
Total Liabilities $767.85M
Stockholders' Equity -$301.96M
Current Assets $462.57M
Current Liabilities $300.81M